Login to Your Account

Beigene’s BGB-3111 goes head to head against Imbruvica in phase III trial for WM

By Shannon Ellis
Staff Writer

Thursday, January 26, 2017

SHANGHAI – Beigene Co. Ltd., of Beijing, is advancing its small-molecule BTK inhibitor candidate, BGB-3111, in a global phase III trial for patients with Waldenström’s macroglobulinemia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription